A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials

被引:82
作者
Hung, HMJ
Wang, SJ
O'Neill, R
机构
[1] US FDA, CDER, OPaSS, Div Biometr 1, Rockville, MD 20852 USA
[2] US FDA, CDER, OPaSS, Div Biometr 2, Rockville, MD 20857 USA
[3] US FDA, CDER, OPaSS, Off Biostat, Rockville, MD 20857 USA
关键词
efficacy; non-inferiority margin; preservation of active control effect; historical trial;
D O I
10.1002/bimj.200410084
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Without a placebo arm, any non-inferiority inference involving assessment of the placebo effect under the active control trial setting is, difficult. The statistical risk for falsely concluding non-inferiority cannot be evaluated unless the constancy assumption approximately holds that the effect of the active control under the historical trial setting where the control effect can be assessed carries to the noninferiority trial setting. The constancy assumption cannot be checked because of missing the placebo arm in the non-inferiority trial. Depending on how serious the violation of the assumption is thought to be, one may need to seek an alternative design strategy that includes a cushion for a very conservative non-inferiority analysis or shows superiority of the experimental treatment over the control. Determination of the non-inferiority margin depends on what objective the non-inferiority analysis is intended to achieve. The margin can be a fixed margin or a margin functionally defined. Between-trial differences always exist and need to be properly considered.
引用
收藏
页码:28 / 36
页数:9
相关论文
共 33 条
[31]   Utility and pitfalls of some statistical methods in active controlled clinical trials [J].
Wang, SJ ;
Hung, HMJ ;
Tsong, Y .
CONTROLLED CLINICAL TRIALS, 2002, 23 (01) :15-28
[32]  
Wang SP, 1997, 12TH SYMPOSIUM ON BOUNDARY LAYERS AND TURBULENCE, P64
[33]   Choosing an equivalence limit for noninferiority or equivalence studies [J].
Wiens, BL .
CONTROLLED CLINICAL TRIALS, 2002, 23 (01) :2-14